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Introduction: Current standard biomarkers in clinic are not specific enough for prostate 
cancer (PCa) diagnosis. Extracellular vesicles (EVs) are nano-scale vesicles released by most 
mammalian cells. EVs are promising biomarker source for PCa liquid biopsy due to its 
minimal invasive approach, rich information and improved accuracy compared to the clinical 
standard prostate-specific antigen (PSA). However, current EV separation methods cannot 
separate pure EVs and the quality characteristics from these methods remain largely 
unknown. In this study, we evaluated the quality characteristics of human plasma-derived 
EVs by comparing three clinical suitable separation kits.
Methods: We combined EV separation by commercial kits with magnetic beads capture and 
flow cytometry analysis, and compared three kits including ExoQuick Ultra based on 
precipitation and qEV35 and qEV70 based on size exclusion chromatography (SEC).
Results: Our results indicated that two SEC kits provided higher EV purity and lower 
protein contamination compared to ExoQuick Ultra precipitation and that qEV35 demon-
strated a higher EV yield but lower EV purity compared to qEV70. Particle number 
correlated very well particularly with CD9/81/63 positive EVs for all three kits, which 
confirms that particle number can be used as the estimate for EV amount. At last, we 
found that several EV metrics including total EVs and PSA-specific EVs could not differ-
entiate PCa patients from health controls.
Conclusion: We provided a systematic workflow for the comparison of three separation kits 
as well as a general analysis process in clinical laboratories for EV-based cancer diagnosis. 
Better EV-associated cancer biomarkers need to be explored in the future study with a larger 
cohort.
Keywords: extracellular vesicles, prostate cancer, lipoprotein, separation, protein biomarker, 
immunomagnetic beads
Introduction
Prostate cancer (PCa) is the most common solid-organ cancer and the second cause of 
cancer death in men, counting 1,276,106 new cases and causing 358,989 deaths in 2018 
worldwide.1 The current diagnostic standard to confirm or exclude PCa is a 12–30 core 
template-guided needle biopsy of the prostate gland. This is an invasive procedure 
associated with risks including pain, complications of general anaesthesia, bleeding, 
psychological distress and post-biopsy infections.2,3 Prostate-specific antigen (PSA) is 
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the current clinical standard for PCa screening and treatment 
monitoring, as many PCa cases are detected based on the 
elevated PSA level (>4 ng/mL) in the serum. However, a rise 
of PSA is also found in men with benign prostatic hyperpla-
sia. Over-diagnosis and over-treatment of PCa due to the 
high false positive of PSA have become an awareness to 
the clinicians.4 Thus, finding novel biomarkers with higher 
specificity to complement or even replace serum PSA has 
attracted clinicians and researchers’ attention.
Extracellular vesicles (EVs) have shown their increas-
ing promise as the next generation of biomarkers for PCa 
diagnosis and management.5–7 EVs consist of 
a heterogeneous population of lipid bilayer-encapsulated 
nanovesicles released by most mammalian cells. EVs are 
circulating within body fluids such as urine, blood, cere-
brospinal fluid and saliva. Thus, EVs separated from can-
cer patients’ biological fluids are able to capture the entire 
heterogeneity of cancer and reflect the tumour change in 
real-time.8 The information cargos, including RNA, lipids, 
proteins and metabolites, carried by EVs are highly corre-
lated to the status of EV parental cells.9–11 Therefore, 
tumour-derived EVs carry important biological informa-
tion about the tumour and become promising biomarkers 
for personalised cancer diagnosis, prognosis and treatment 
monitoring.12,13
As a major resource of EVs, blood is of the most interest 
due to its great accessibility to clinicians, accurate reflection 
of the circulation status, and easy implementation for clin-
ical analysis.14,15 Compared to serum, plasma is a more 
native sample to represent the real circulatory system as it 
avoids additional EV released from platelet during the clot-
ting process associated with serum.14,16 However, plasma is 
a very challenging sample to work with. Substantial evi-
dence shows the presence of a high degree of contaminants 
in vesicle isolates including non-EV proteins and lipopro-
teins regardless of the separation method used.17–19 It has 
been shown that lipoproteins are co-separated with EVs 
from plasma with several orders higher magnitude.20 
Therefore, it is essential to evaluate the EV quality thor-
oughly when investigating a separation method before mov-
ing towards the actual clinical application.
Currently, differential ultracentrifugation (UC) is con-
sidered as a standard method for EV separation.21 
However, UC is not suitable for clinical use as it is time- 
consuming, labour intensive, requiring special and expen-
sive instrument.22–24 In particular, the EV yield from UC 
has shown to be very low, which cannot be used in some 
downstream analysis with limited sensitivity.21,24 To 
address the challenges for routine EV separation, numer-
ous techniques have been developed. Among a variety of 
separation methods, size-exclusion chromatography (SEC) 
has been widely explored considering its relatively simple 
workflow, shorter operation time, and a good balance 
between the EV yield and purity.25 Polymer precipitation 
is another convenient method aiming towards maximising 
EV yield, but it usually introduces high levels of contam-
inations when using complex sample sources such as 
plasma.16 Whilst polymer precipitation combined with 
extra purification may be a good option to improve purity.
Numerous studies compared different EV separation 
methods and the International Society for EVs (ISEV) 
has established several guidelines for the standardisation 
of EV separation and quality assessment.26–28 However, 
only a few of these comparison works used actual cancer 
patient plasma samples with a thorough EV quality assess-
ment in the scenario of clinical cancer diagnosis.29,30 In 
this study, we established a quantitative quality assessment 
using several separation kits suitable for clinical use that 
we are particularly interested in: ExoQuick® ULTRA 
(ExoQuick Ultra) which combines precipitation and resin 
purification and qEV/35nm (qEV35) and qEV/70nm 
(qEV70) as SEC-based method. The whole workflow is 
shown in the flow chart in Figure 1. We aim to provide 
a systematic guideline for the quality assessment and 
comparison of the separation methods based on several 
key parameters: EV yield, EV purity, lipoprotein contam-
ination and protein contamination. The quantitative assess-
ment of these parameters was carried out using 
immunomagnetic beads capturing following by flow cyto-
metry analysis. We further showed that particle number is 
an appropriate estimate for EV amount in plasma, as it has 
good correlations with EV yields for all three kits. At last, 
we assessed the capability of several EV metrics including 
total EVs and PSA-specific EVs for differentiating PCa 
patients from healthy donors. From these findings, we 
hope to provide a systematic workflow and our insights 
for EV-based separation and analysis in the clinical setting, 
particularly for cancer diagnosis.
Materials and Methods
Clinical Samples
A total of 12 non-fasting individuals were enrolled in the 
study. Patients with localised PCa (n=6) were recruited 
from Hurstville Private Hospital (Sydney, NSW, 
Australia) according to South Eastern Sydney Local 
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Health District Human Research Ethics Committee proto-
col with informed consent (HREC ref no: 12/131). 
Pathological information of PCa patients including serum 
PSA, risk group, Gleason score and tumour stage was 
obtained from Douglass Hanly Moir pathology lab 
(Macquarie Park, NSW, Australia). Age-/gender-matched 
healthy volunteers (n=6) were recruited from Australian 
Red Cross Blood Service (Agreement no: 18–07NSW-04, 
UNSW HC no: 180390). Peripheral blood was drawn into 
K2EDTA tubes (BD bioscience, San Jose, CA, USA). The 
blood was processed within 2 hours of blood collection. 
Plasma was extracted after the first centrifugation of the 
blood at 3000 rpm for 15 min at 4 °C. The plasma was 
immediately transferred into a clean tube without disturb-
ing the buffy coat and followed by serial pre-purification 
steps at 4 °C as follows: Plasma was spun at 2000 × g for 
20 min and the supernatant was centrifuged at 10,000 × 
g for 20 min to remove cells and debris. The supernatant 
was then filtered through 0.22 µm pore Ultrafree centrifu-
gal filter (Merck KGaA, Darmstadt, Hesse, Germany) at 
12,000 × g for 2 min. Aliquots of the purified plasma 
samples were stored at −80 ֯C and freeze-thawing was 
limited within two cycles for each sample.
Separation of EVs from Plasma
EVs from plasma from the same participant were sepa-
rated by three kits for comparison (Figure 1): ExoQuick® 
ULTRA (System Biosciences, Palo Alto, CA, USA), 
qEV35 and qEV70 (IZON Science, Christchurch, 
Canterbury, New Zealand). EVs from 250 μL pre- 
purified plasma were separated according to the manufac-
ture’s protocols. For qEV35 and qEV70 SEC columns, the 
purified plasma aliquot was loaded on the SEC column, 
and the 7–9 fraction (a total of 1.5 mL) sample was 
collected in the recommended EV elusion zone for con-
sistent results and highest purity. Strategies for character-
ising different SEC fractions were provided in previous 
publications.24,31 Therefore, we followed the manufac-
turer's protocol in this study. A post-enrichment step to 
obtain a higher EV concentration was performed using 
Amicon® Ultra-4 10 KDa unit (Merck KGaA, Darmstadt, 
Hesse, Germany). For ExoQuick ULTRA, plasma samples 
were incubated with ExoQuick reagent for 30 min at 4 °C 
followed by a 10 min centrifugation at 3000 × g. Pellets 
were collected and resuspended in 200 μL Buffer B of 
ExoQuick Ultra. Another 200 μL Buffer A was added to 
resuspended EVs. The entire content was loaded to a pre- 
Figure 1 Flow chart of the whole workflow of EV separation and analysis.
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cleaned resin column with another 100 μL Buffer B added 
previously. After mixing, purified EVs were collected by 
centrifugation at 1000 × g for 2 min. All separated EVs 
were aliquoted and stored at −80 °C. EV samples are used 
within two freeze-thawing cycles for the following 
analysis.
Nanoparticle Tracking Analysis (NTA)
NTA was performed on NanoSight LM14 system 
(NanoSight Technology, Malvern, Worcestershire, UK) 
equipped with a 532 nm green laser for determining the 
EV concentration and size distribution. Briefly, 10 μL 
separated EV samples were diluted with freshly 0.22 μm 
filtered PBS and loaded into the detection chamber by 
syringe. The same settings were used: camera level: 11, 
detect threshold: 14, capture: 60 s, number of capture: 5, 
temperature: 25 °C. The data were processed by NTA 
software (NTA version 3.3; Malvern Instruments, 
Malvern, Worcestershire, UK). A series of known numbers 
of 100 nm silica microspheres (Polysciences, Inc, catalog 
No: 24,041–10, Warrington, PA, USA) were used for the 
calibration of our measurement before using any EV sam-
ples. EV isolates from three kits were diluted to the opti-
mum NTA detection range (1–10 × 108 particles/mL) 
before measurement.32,33 The same Nanosight parameters 
were used for all samples for a consistent comparison. The 
original particle concentrations from the isolates were then 
calculated based on the measured concentrations and the 
dilution factor.
Protein Quantification Assay
Qubit protein assay kit (Life Technologies, catalog No. 
Q33211, Carlsbad, CA, USA) with the Qubit fluorometer 
was used for protein content quantification. The assay was 
performed according to the manufacture’s instruction. 
Briefly, 1–20 µL isolates were mixed with Qubit working 
solution to a final reaction volume of 200 µL. The reaction 
was incubated at room temperature for 15 min. Samples 
were read on a Qubit fluorometer after the calibration, 
which was done by the fluorometer automatically with 
three Qubit standards.
EV Antibody Array
The immunoblotting analyses of EV-specific markers 
were performed to validate the separated EVs using 
a commercial Exo-Check™ Exosome Antibody Array 
(Neuro) Mini (System Biosciences, Palo Alto, CA, 
USA). The same amount of EV preparations (12.5 μg) 
was added to the membrane-based blot array and the 
manufacturer’s instruction was followed. Briefly, EV 
sample was lysed by lysis buffer and labelled by the 
labelling reagent. The labelled EV sample was then 
washed through the column and blocked by 5 mL block-
ing buffer with mixing. An EV array membrane was 
incubated with 5 mL labelled EV lysate/blocking buffer 
mixture at 4 °C overnight with shaking. Membrane was 
washed with wash buffer and incubated with detection 
buffer in the next day followed by developing and 
imaging.
Conjugation of Streptavidin Magnetic 
Beads with Biotinylated ApoB
Anti-ApoB conjugated magnetic beads were used to speci-
fically capture lipoproteins in the EV isolates.20 ApoB anti-
body (Abcam, catalog No. ab20898, biotinylated, 
Melbourne, VIC, Australia) was added to 1× PBS with 
0.1% Tween 20 (1× PBST) to a final concentration of 20 
μg/mL. 0.2 mL of streptavidin magnetic beads (4.5 μm, 1.0 
× 107/mL, ThermoFisher Scientific, catalog No. 10608D, 
Waltham, MA, USA) were washed with 1× PBST. 0.2 mL 
biotinylated ApoB antibody was incubated with the beads 
for 2 hr at 4 °C. The conjugated beads were washed with 1× 
PBST followed by a wash of 1× PBS with 2% BSA and 
stored in 0.2 mL of 1× PBS with 2% BSA at 4 °C.
Immunomagnetic Beads Capturing
Immunomagnetic beads capturing was applied to exploit 
EV quality based on the commonly used EV surface 
markers and lipoprotein contamination based on ApoB 
marker. The same particle numbers of EV samples mea-
sured by NTA were incubated with antibody-conjugated 
magnetic beads for the specific capturing in 200 µL PBS 
with 2% BSA overnight at 4 °C. A mixed capturing beads 
were used with the same beads numbers: 10 µL anti-CD9 
magnetic beads (2.7 μm, 1.0 × 107/mL, ThermoFisher 
Scientific, catalog No. 10620D, Waltham, MA, USA), 
anti-CD81 magnetic beads (2.7 μm, 1.0 × 107/mL, 
ThermoFisher Scientific, catalog No. 10622D, Waltham, 
MA, USA) and customised ApoB magnetic beads (based 
on 4.5 μm streptavidin magnetic beads mentioned pre-
viously). The EV-captured beads were washed twice with 
PBS with 2% BSA. All the beads separation steps were 
performed on a MagJET separation rack (Thermo Fisher 
Scientific, Waltham, MA, USA).
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Flow Cytometry Analysis of Beads 
Captured EV
After binding, EVs captured by magnetic beads were stained 
with respective detection antibody for flow cytometry analy-
sis. The following antibodies were used: a mixture of APC- 
conjugated anti-CD9 (Thermo Fisher Scientific, catalog No. 
A15698, Waltham, MA, USA), anti-CD81 (Biolegend, cata-
log No. 349,510, San Diego, CA, USA) and anti-CD63 
(Thermo Fisher Scientific, catalog No. A15712, Waltham, 
MA, USA) for a hybridised EV detection; Alexa Fluor 405- 
conjugated anti-PSA (Novus Biologicals, catalog No. NBP2- 
34549AF405, Littleton, CO, USA); FITC-conjugated anti- 
Apolipoprotein B (Abcam, catalog No. ab27637, Melbourne, 
VIC, Australia) for the detection of lipoprotein; The follow-
ing isotype controls were used during the flow cytometry: 
APC-conjugated anti-Mouse IgG1 (Thermo Fisher 
Scientific, catalog No. MA518093, Waltham, MA, USA); 
Alexa Fluor 405-conjugated anti-Mouse IgG1 (R&D 
Systems, catalog No. IC002V, Minneapolis, MN, USA); 
FITC-conjugated anti-Goat IgG (Abcam, catalog No. 
ab37374, Melbourne, VIC, Australia). The detection antibo-
dies were incubated with EV-captured beads at 4 °C in dark 
for 30 min. After staining, the beads were washed twice with 
100 µL PBS with 2% BSA to remove residue stains in the 
solution. 500 µL PBS was added to the bead pellets for the 
analysis on FACS Canto II (Becton Dickinson, Franklin 
Lakes, NJ, USA) flow cytometry and the data were processed 
and analysed by FlowJo software (Version 10). By gating 
different groups in the scattering plot of flow cytometry data 
and using different fluorescence stains, we can analyse EVs 
and lipoproteins simultaneously (Figure S1a). We used the 
ratio between the geometric mean of fluorescence intensity 
(gMFI) from each marker and that from IgG isotype control 
to quantify each marker level (Figure S1b-d): Relative fluor-
escence intensity (RFI) = gMFI of detection Ab/gMFI of IgG 
isotype control.
Cryogenic Electron Microscopy 
(Cryo-EM)
Cryo-EM was used to determine the morphologies of EV 
samples. 4 μL EV isolates were applied to glow- 
discharged copper grids (Quantifoil R2/2, Quantifoil 
Micro Tools). The grids were blotted for 3 s at 4 °C with 
90% humidity and plunged into liquid ethane using 
a Lecia EM GP device (Leica Microsystem, Wetzlar, 
Hesse, Germany). The vitrified samples were stored in 
liquid nitrogen (−196 °C) prior to cryo-TEM analysis. 
Cryo-EM data were collected on a Thermo Fisher Talos 
Arctica transmission electron microscope operated at 200 
kV acceleration voltage. Images were recorded on a Falcon 
III detector (Thermo Fisher Scientific, Waltham, 
MA, USA).
Statistical Analysis
One-way ANOVA with post hoc multiple comparison cor-
rection was used to determine statistically significant dif-
ferences among separation method groups and two-tail 
t-test was used between PCa patients and healthy controls. 
All analyses were performed with GraphPad Prism 7 
(Graph Pad Software, San Diego, CA, USA). Data are 
plotted as mean ± SD. Statistical significance was indi-
cated as follows: *P < 0.05, **P < 0.01, ***P < 0.001, 
****P < 0.0001.
EV-TRACK
The relevant data was submitted to the EV-TRACK 
knowledgebase (EV-TRACK ID: EV200020), as sug-
gested by a previous guideline.34
Results
We used the same volume of 250 μL plasma from the 
same participant for all the three separation kits in each 
separation. This pair-to-pair comparison from the same 
participant and repeated separation processing makes our 
comparisons more convincing and accurate. The compar-
ison results among three different kits were from both PCa 
patients (n=6) and healthy donors (n=6).
Particle Size Distribution and 
Concentration
Nanoparticle tracking analysis (NTA) is the most widely 
used instrument for characterising the particle size and 
concentration of EV samples.32,33 Before using the EV 
samples, we used silica microspheres, which have 
a refractive index close to EVs for the calibration of our 
measurement as suggested by a previous report.33 Our 
analysis results showed a narrow particle size distribution 
and a good linear relationship between the theoretical and 
known particle concentrations (Figure S2). The calibration 
process confirms the reliability of our NTA measurements.
Detailed information for particle size distributions and 
related analysis is shown in Figure 2A–C. Each curve in 
Figure 2A was from an average of 12 samples including 
PCa patients and healthy controls (HC). The results 
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indicate that the particle size distributions between qEV35 
and qEV70 were similar in the range <130 nm, while 
qEV70 started to collect a larger portion of particles 
>130 nm compared to qEV35. Compared to the two SEC 
kits, the histogram from ExoQuick Ultra had an obvious 
peak shift to the larger size range, which indicates that it 
collected a greater portion of larger particle size composi-
tion or formed more aggregations during precipitation. The 
detailed size distributions are shown in Figure 2B by 
fractionating particles into 4 size ranges: <100 nm, 
100–150 nm, 150–200 nm and >200 nm. The results 
suggest that the particles from 100–150 nm had the largest 
portion for all three kits and qEV35 collected the highest 
portion of particles in the <100 nm range. This is under 
expectation as qEV35 uses a smaller pore size as the cutoff 
so more smaller particles can be collected compared to 
qEV70.
It is noteworthy that there are still some particles >200 
nm for all methods even though we used a 0.22 μm filter to 
filtrate the plasma before separation. The modal particle sizes 
for each method are presented in Figure 2C, with Exoquick 
Ultra 141.9 ± 12.5 nm, qEV35 120.6 ± 14.9 nm, and qEV70 
127.7 ± 10.4 nm, respectively. The mode size from ExoQuick 
Ultra samples was significantly larger than those from the 
two SEC kits but there is no significant difference between 
qEV35 and qEV70 (One-way ANOVA). The particle 
Figure 2 Particle size distribution and concentration of samples separated using three kits from both PCa patients (n=6) and HC (n=6). (A) Particle size distributions 
between qEV35 and qEV70 were similar in the range <130 nm, while qEV70 started to collect a larger portion of particles >130 nm. ExoQuick Ultra has an obvious peak 
shift to the larger size range. The histograms are presented as the average from 12 samples (solid curves) with standard error (vertical red error bar); (B) Percentage of total 
particles falls into 4 different size fractions: <100 nm, 100–150 nm, 150–200 nm, >200 nm. Particles from 100–150 nm have the largest portion for all three kits. qEV35 
collected the highest portion of particles in the ≤ 100nm range. (C) Particle mode sizes: Exoquick Ultra 141.9 ± 12.5 nm, qEV35 120.6 ± 14.9 nm, and qEV70 127.7 ± 10.4 
nm. The mode size from ExoQuick Ultra samples was significantly larger than those from the two SEC kits. No significant difference was found between qEV35 and qEV70 
kits. (D) Particle concentrations calculated into per mL plasma. The number of particles was significantly lower (10 orders of magnitude lower) in qEV70 compared to qEV35 
and ExoQuick Ultra. No significant difference between ExoQuick Ultra and qEV70. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001. One-way ANOVA with post hoc 
multiple comparison correction was used for c-d.
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concentrations in the original EV isolates are shown in 
Figure 2D. Obviously, the number of particles was signifi-
cantly lower (10 orders of magnitude lower) in qEV70 com-
pared to qEV35 and ExoQuick Ultra, and no significant 
difference was observed between qEV35 and ExoQuick 
Ultra (One-way ANOVA). As NTA is a non-specific method 
for all particles, it cannot distinguish EVs from similar size 
particles such as lipoprotein and protein aggregates.19 
Therefore, we performed a more specific beads-based flow 
cytometry analysis to confirm if the higher particle numbers 
from qEV 35 and ExoQuick Ultra are associated with more 
EVs, which will be presented later in the paper.
EV Validation Using Immunoblotting and 
Cryo-EM
The ISEV suggested using different characterisation techni-
ques to validate the EV presence such as common EV bio-
markers and morphological structures using electron 
microscopy.26,27 To obtain a profile of EV protein content, 
a commercial protein array (Exo-Check™ Exosome 
Antibody Array) was used to determine the presence of 
commonly used EV markers CD81 and TSG101 and 
a negative marker calnexin (CANX) which should not be 
present in EVs of endosomal origin. The advantage of this 
array compared to standard Western blotting (WB) is that the 
results from different markers can be obtained in one mem-
brane, which eliminates the errors introduced by operation 
variations between different membranes in standard WB. As 
shown in Figure 3, all three kits showed a positive signal in 
CD81 and TSG101. While qEV35 sample showed a slightly 
positive signal in CANX, samples from qEV70 and 
ExoQuick Ultra are negative to CANX. This negligible/slight 
CANX level indicates the absent or under-represented larger 
EV subtypes associated with compartments other than 
plasma membrane/endosomes under the secretory pathway.
In addition, we also used cryo-EM to observe the 
morphologies of the EV isolates. Compared to conventional 
transmission EM which shows a “cup-shaped” structure, 
cryo-EM is more suitable for EVs as it maintains the original 
shape of EVs and allows a clear observation of the lipid 
bilayer structure. Importantly, cryo-EM allows the differen-
tiation between EVs and other contaminations especially 
lipoproteins, as lipoproteins are shown as electron-dense par-
ticles without lipid bilayer.18 This feature is especially useful 
to inspect EV samples from plasma in which lipoproteins are 
the major contamination. We presented several representative 
cryo-EM images from isolates of the same PCa patient using 
the three kits (Figure 4). All the images confirmed the pre-
sence of EVs, which have clear bilayer structures (yellow and 
red arrows). Interestingly, EVs separated from plasma are 
highly heterogeneous in morphology from all three kits, 
including single vesicle (in Figure 4A, D, G), double vesicles 
(in Figure 4A and H), multilayer vesicles (in Figure 4B and 
E) and incomplete vesicles with partial bilayer (in Figure 4I). 
The multilayer-vesicle structure in Figure 4B (red arrow) was 
confirmed using 3D cryo-EM to exclude the possibility of 
overlapped EVs (Supplementary Video). This result of het-
erogeneous EV structures is consistent with previous studies 
that used cryo-EM to inspect EVs from both plasma and 
cerebrospinal fluid.18,35 In the background of Figure 4C–I, 
there are a large number of smaller dense particles without 
bilayer (white arrows). Similar structures were observed in 
the previous study by Yuana et al, which can be classified as 
very low-density lipoproteins (VLDL) and low-density lipo-
protein (LDL) judging from their sizes.19 The presence of 
VLDL and LDL is consistent with previous reports which 
showed that SEC could only remove the small and most 
abundant high-density lipoprotein (HDL).20,30
Quality Assessment Using 
Immunomagnetic Microbeads Followed 
by Flow Cytometry
To assess the EV quality from the three separation kits, we 
employed magnetic microbeads to specifically capture tar-
geted analytes based on immunoaffinity-binding, followed 
Figure 3 Representatives of immunoaffinity blotting for typical EV marker expres-
sion (12.5 μg protein loading). The EV samples from PCa patients showed the 
presence of CD81, TSG101 markers and absence of Calnexin (CANX) marker. 
Blank: assay running with PBS instead of sample. The red dotted boxes highlighted 
the location of individual blots. 
Abbreviations: PC, positive control; NC, negative control
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by a conventional flow cytometry analysis. We used 
a mixture of beads with two distinguished sizes: 2.7 μm 
beads with anti-CD9/CD81 to capture EVs and 4.5 μm 
beads with anti-ApoB to capture lipoproteins, so that EVs 
and lipoproteins can be interrogated simultaneously. We 
used a hybridised fluorescence detection with three com-
monly used EV markers (CD63, CD81 and CD9) to provide 
an overall EV quantification. The same number of particles 
measured by NTA was used as the loading dosage in bead 
incubation for a quantitative comparison between three kits. 
We used several key metrics based on the relative fluores-
cence intensity (RFI) from the detection markers to assess 
the separation quality of three kits: EV yield (CD63/9/81 
level in the same plasma volume), EV purity (the ratio 
between EV yield and protein amount), lipoprotein contam-
ination (ApoB level in the same plasma volume) and protein 
contamination (the protein amount in the same plasma 
volume). Details for flow cytometry quantification are dis-
cussed in the method section. All comparisons between the 
three kits were performed by one-way ANOVA with post 
hoc multiple comparisons.
The schematic of the immunomagnetic beads capture is 
shown in Figure 5A. The successful immunoaffinity binding 
between beads and EVs can be confirmed by our previous 
Figure 4 Representative Cryo-EM images showing different EV structures from the same PCa patient using the three kits. Samples from all three kits contain EVs (yellow 
and red arrows) with heterogenous structures such as single vesicles (A, D, G), double vesicles (A and H), multilayer vesicles (B and E) and incomplete vesicles (I). There 
are large numbers of electron-dense particles in the background (C–I) which are assumed to be lipoproteins in the background for samples from all three kits (white 
arrows). Scale bar: 200 nm. The multilayer-vesicle structure in (B) pointed by red arrow was characterised by 3D cryo-EM to exclude the possibility of overlapped EVs 
(Supplementary Video).
submit your manuscript | www.dovepress.com                                                                                                                                                                                                                    
DovePress                                                                                                                                       
International Journal of Nanomedicine 2020:15 10248





































































Powered by TCPDF (www.tcpdf.org)
                               1 / 1
data using EVs separated from a pancreatic cancer cell line 
(PANC1). The scanning electron microscopy images in the 
right images in Figure 5A show that the surface of the bead 
coated with anti-CD9 (top image) was covered with brighter, 
small particulate structures which were the captured EVs, 
while the control IgG coated bead (bottom image) had 
negligible binding after incubation with EVs.
EV quality. Figure 5B shows the EV yields from the 
same volume of 250 μL plasma. Significant higher CD9/ 
81/63 signals were detected in samples from qEV35 and 
ExoQuick Ultra compared to qEV70, suggesting 
a significantly higher EV yield. The EV yields from qEV35 
and ExoQuick Ultra have no significant difference, while the 
variation among different samples is quite large for qEV35. 
In contrast, the EV purity from qEV70 is higher than the 
other two kits, judging from its higher ratio between EV 
yield and the protein contamination as shown in Figure 5C. 
ExoQuick Ultra provided the lowest EV purity, which indi-
cates the purification column accompanied by the precipita-
tion kit could not improve the purity effectively compared 
with the SEC kits. We also employed the widely used 
particle number/protein ratio to evaluate the EV purity 
(Figure 5G), in which a higher ratio indicates a higher 
purity.36 The results are consistent with Figure 5C when 
using specific EV RFI in terms of ExoQuick Ultra providing 
the lowest purity compared to the two SEC kits.
Lipoprotein contamination. EVs significantly overlap 
with VLDL and chylomicrons in particle size and with 
HDL in particle density.19 Therefore, it is almost impos-
sible to remove lipoproteins from EVs when using plasma 
sample. The amount of lipoproteins is several orders of 
magnitude higher than EVs,19 so it is very important to 
assess the lipoprotein contamination when using any 
separation methods. ApoB was chosen as a general bio-
marker to evaluate the lipoprotein contamination as pre-
vious work showed that LDL is predominant in the 
lipoprotein particles co-separated with EVs and that com-
mercial anti-ApoB antibody can recognise apoB48 variant 
for chylomicrons and apoB100 variant for VLDL/ 
LDL.19,20 Our results show that qEV70 provides the low-
est lipoprotein contamination (obtained from the ApoB 
RFI) among all three separation kits (Figure 5D). When 
comparing the relative ratios between lipoproteins and 
EVs, qEV70 is also the lowest among the three kits 
(Figure 5E), which indicates qEV70 can provide the lar-
gest EVs portion relative to lipoproteins. These results 
indicate that even though SEC has been reported with 
the capability to remove the majority of HDL,16,31 it is 
Figure 5 EV quality assessment from both PCa patients and HC samples from three different kits. (A) Schematic diagram of EVs capturing by immunomagnetic beads. Right: 
Scanning electron microscopy images of the EV binding on CD9 bead and negligible non-specific binding on IgG control bead. Scale bar: 500 nm. (B) Significant higher CD9/ 
81/63 signals were detected in samples from qEV35 and ExoQuick Ultra compared to qEV70, suggesting a significantly higher EV yield. The EV yields from qEV35 and 
ExoQuick Ultra have no significant difference. (C) qEV70 provides a higher EV purity than the other two kits, while ExoQuick Ultra provided the lowest EV purity. (D and E) 
qEV70 provides the lowest lipoprotein contamination and Lipoprotein/EV ratio. (F) Protein contamination from ExoQuick Ultra is 4 times of that from qEV35 and 33 times 
of that from qEV70. (G) Particle/protein ratio shows ExoQuick Ultra provides the lowest purity. Sample number: n=12 for (B, D, E) (from 6 patients and 6 HC); n=6 for (C, 
F, G) (from 3 patients and 3 HC). *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001. One-way ANOVA with post hoc multiple comparison correction was used for (B–F).
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not effective to remove other types of lipoproteins such as 
VLDL and LDL.
Protein contamination. As plasma is quite complex 
media to work with, it is inevitable that EV isolates con-
tain other non-EV proteins such as free albumin if the 
separation method is only based on physical characteristics 
such as density, solubility or size. Thus quantification of 
the protein contamination can help evaluate the EV purity. 
Figure 5F shows that the protein contaminations from the 
three kits have an opposite order against EV purity shown 
in Figure 5C. The protein contamination from ExoQuick 
Ultra (841.52 μg) is remarkable higher, which is 4 times of 
that from qEV35 (209.94 μg) and 33 times of that from 
qEV70 (25.59 μg).
Overall, the quality assessment from the three separa-
tion kits shows that ExoQuick Ultra has the most contam-
inations especially non-EV proteins compared with the 
SEC method. This confirms that polymer precipitation is 
not recommended for pursuing high purity, even though 
a purification column is supposed to improve it. In con-
trast, qEV70 is the best option regarding the EV purity 
with the least non-EV protein contamination and lipopro-
tein contamination. qEV35 provides the best EV yield and 
can provide a balance between the yield and purity. The 
comparison between qEV35 and qEV70 indicates that the 
smaller pore size in SEC column with qEV35 does help 
with the collection of more EVs, but it also collects more 
contamination particles such as lipoproteins.
The Capability of Using Particle Number 
as the Estimate of EV Amount
For quantitative clinical analysis, it is important to choose 
the right estimate for the loading of equal EV amount to 
make the analytical results comparable. We initially chose 
particle number as the dosage due to a lack of sensitivity 
of commonly used protein quantification method such as 
bicinchoninic acid assay (BCA) assay from limited plasma 
volume. Therefore, it is very necessary to assess if the 
particle number has the capability to estimate EV amount 
for different separation kits.
The correlations of particle numbers to the EV amount 
(quantified by CD9/81/63 RFI) for each separation kit are 
plotted in Figure 6A–C. Strong positive correlations were 
observed for all the separation kits (ExoQuick Ultra: 
p<0.0001, R2=0.9186; qEV35: p<0.0001, R2=0.9557; 
qEV70: p<0.0001, R2=0.8774), which confirms that the par-
ticle number has the capability to reflect the actual EV 
amount from plasma. Thus, equal particle numbers can be 
used for EV loading for quantification. The correlations 
between measured particle number and protein amount 
were also investigated (Figure 6D–F). Among the three 
separation kits, only qEV70 provided a strong correlation 
(p<0.0001; Figure 6F). The lack of linearity with the other 
two kits may be due to the missing of more abundant smaller 
particles during NTA measurement which makes the actual 
particle measurement inaccurate.21 Therefore, for qEV70 
both particle number and protein amount can be used to 
estimate EV amount; while for qEV35 and ExoQuick Ultra 
more investigation is required to examine if protein amount 
can be used as the estimate or not.
Differentiation Between PCa Patients and 
Healthy Donors
As our goal is to use EVs to improve PCa diagnosis, we 
looked at the capabilities of separated EVs for differentiat-
ing PCa patients with HC and compared the results from 
different separation kits. A table of PCa patients’ informa-
tion was provided including ages, risk group, serum PSA 
level, Gleason score, and the tumour/node/metastasis 
(TNM) stage (Supplemental information, Table S1).
It is important and challenging to choose the right EV 
metrics for the differentiation of different separation meth-
ods. In circulation, tumour-derived EVs are mixed with 
EVs derived from normal cells, which might affect the 
ability to identify and analyse tumour-derived EVs. 
Therefore, it is critically important to select the right 
biomarkers from cancer-derived EVs for cancer diagnosis. 
Commonly used EV metrics from previous studies include 
the total EV content and cancer-specific EVs.38–40 In this 
study, we also investigated these metrics for the three 
separation kits. For cancer-specific EVs, we chose PSA 
as a starting point as it is the current clinical standard for 
PCa screening. We investigated if EVs carry PSA and 
whether PSA-specific EVs can assist the PCa diagnosis. 
This was achieved by staining EVs captured by CD9 and 
CD81 beads with anti-PSA antibodies, so that the PSA 
fluorescence signals are specifically from EVs instead of 
other co-separated free PSA.
The comparison (two-tail t-test) between different EV 
metrics among the three separation kits is shown in Figure 7. 
Strong fluorescence signals were observed in PSA stained 
EVs for all three kits, which confirms that EVs carry PSA on 
their surface (Figure S1d). However, no significant difference 
was observed between PCa patients and HC based on PSA- 
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specific EVs for all the three kits (Figure 7A–C). This result 
indicates that similar with free PSA, PSA-specific EVs also 
lack the specificity to differentiate between PCa patients and 
HC, which is consistent with the previous study by Liu et al.41 
We also attempted to use the ratio between PSA-specific EVs 
and total EVs, hoping for a more accurate evaluation of PSA- 
specific EVs, since samples from PCa patients contain both 
cancer-derived and normal EVs. As shown in Figure 7D–F, 
only qEV70 shows some difference between PCa patients and 
HC, yet HC shows a higher ratio of PSA+ EVs/Total EVs, 
which is not what we expected as a PCa patient usually has 
elevated PSA level (>4 ng/mL) in the serum compared to 
a healthy person. This again indicates that EV-associated 
PSA lacks the specificity to differentiate between PCa patients 
and HC. Total EVs could not be used to differentiate PCa 
patients and HC for all three kits either, as shown in 
Figure 7G–I. This is understandable considering again sam-
ples from PCa patients contain both cancer-derived and nor-
mal EVs. Therefore, other EV associated biomarkers with 
a higher specificity to differentiate between PCa patients and 
HC are to be explored in our future work with a larger cohort.
Discussion
EVs have attracted tremendous attention as new biomar-
kers for liquid biopsy-based cancer diagnosis. For 
instance, Royo et al found that EVs protein markers 
(FLOT1, CD63) were alterated in urine samples from 
PCa patients (n=18), suggesting EVs are feasible for 
using a small volume of urine samples in the clinical 
setting.29 Melo et al analysed EVs from 190 pancreatic 
ductal adenocarcinoma (PDAC) patients and 32 breast 
cancer patients, and demonstrated a strong correlation 
between GPC1+ EVs and cancer, particularly for PDAC, 
inferring that GPC1+ EVs may serve as a potential bio-
marker to detect early stages of pancreatic cancer.38 
These findings indicate the clinical significance of EV- 
associated biomarkers in cancer diagnosis. However, cur-
rent EV diagnostic strategies are still far away from 
clinical translation. One important reason is that currently 
there is no standard method for EV separation, even 
though 190 distinct separation methods are used in pre-
vious studies.34 Choosing different separation methods 
may result in a different portion of EVs, co-separated 
lipoproteins and soluble proteins, which would affect 
downstream analysis such as protein and particle content, 
phenotype, and molecular cargos.29,37 Therefore, know-
ing the quality from the separation method is essential for 
choosing the suitable method and ensuring the accuracy 
of downstream applications. In this study, we provided 
a systematic protocol for a thorough investigation of the 
separation quality by a representative comparison 
between three attractive kits suitable for clinical use. 
Figure 6 (A–C) Correlation between particles number and EV yield (from 6 patients and 6 HC). Strong positive correlations were observed for all the separation kits. (A) 
ExoQuick Ultra: R2=0.9186, P<0.0001; (B) qEV35: R2=0.9557, P<0.0001; (C) qEV70: R2=0.8774, P<0.0001. (D–F) Correlation of particles number to the protein amount 
(from 3 patients and 3 HC). Only qEV70 provided a strong correlation. (D) ExoQuick Ultra: R2=0.03332, P=0.7292; (E) qEV35: R2=0.4067, P=0.1731; (F) qEV70: R2=0.9875, 
P<0.0001.
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Our strategy, using a combination of the commercially 
available separation kit with magnetic beads capture and 
flow cytometry analysis, provides a complete workflow 
for clinical EV analysis which can be easily and directly 
implemented in clinical laboratories.
SEC is gaining increasing popularity owning to its 
simple procedure compared to UC and a relatively 
good balance between EV purity and yield.21 We per-
formed a pair-to-pair quantitative comparison of two 
popular SEC kits (qEV70 and qEV35) with 
a purification included polymer precipitation kit 
ExoQuick Ultra. We found that the SEC kits provided 
higher EV purity compared to ExoQuick Ultra. 
Exoquick Ultra provided an EV yield comparable with 
qEV35, but the EV purity was sacrificed with high 
levels of lipoprotein and protein contaminations. 
Between the two SEC kits, qEV70 provides the best 
EV purity while qEV35 provides the best EV yield. 
Researchers are suggested to choose the separation 
method depending on the downstream application. For 
instance, if the downstream analysis has high-enough 
sensitivity, qEV70 is a recommended method as it 
provides the highest purity. On the other hand, if the 
analysis requires a larger EV amount, qEV35 may be 
the better option with the highest yield. However, extra 
caution needs to be taken into consideration to ensure 
that the results are specifically from EVs instead of 
other contaminations such as lipoproteins.
Figure 7 Comparison between PCa patients (n=6) and health control (n=6) using different EV metrics with three different kits. (A–C) PSA positive EVs, (D–F) PSA positive 
EVs/total EVs, and (G–I) Total EVs. No significant difference was observed between PCa patients and healthy controls (HC) based on PSA-specific EVs or total EVs for all the 
three methods. Only qEV70 shows some difference between PCa patients and HC when using PSA positive EVs/total EVs as the metrics. As different fluorescence stains in 
the detection marker were used for PSA and EVs (Alexa Fluor 405 for PSA and APC for EVs), the fluorescence signals from PSA is more intensive than EVs, which leads to 
the RFI ratio of PSA+ EV/total EV >1. *P < 0.05. Two-tail t-test was used for (A–I).
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Human plasma provides highly valuable information 
and clinical relevance which benefit the utilisation of EV- 
associated biomarker from lab bench to clinic bedside. 
However, plasma is a very challenging biofluid to work 
with as it is a complex medium with different contamina-
tions especially lipoproteins which are several orders of 
magnitude higher than that of EVs.19 As lipoproteins share 
similar size and density with EVs, they are very difficult to 
remove using a single separation method based on physi-
cal characteristics. A combination of several separation 
methods is a trend, which has been applied in a lot of 
studies.15 Several proteins were reported as specific mar-
kers for a variety of lipoprotein subtypes, such as ApoA1, 
ApoB48 and ApoB100.17,20,42 ApoA1 is majorly asso-
ciated with HDL, and previous researches have shown 
SEC can remove >95% HDL.19,31 Therefore, in this 
study, we used ApoB expression as the metrics to evaluate 
the lipoprotein level, which was also utilised by previous 
studies.20,43 Our results show that lipoproteins are inevi-
table for all three separation kits, and SEC which was 
reported to be effective to remove smaller HDL cannot 
remove other types such as LDL and VLDL sufficiently. 
This issue makes an extra step of immunoaffinity-based 
separation such as the immunomagnetic beads used in our 
study essential.
As the two SEC kits, qEV35 and qEV70, are based on 
two pore sizes targeting different cutoffs, we are interested 
in investigating the difference between their separation 
products. Our results showed that qEV35 indeed collected 
more particles <100 nm compared to qEV70 and 
ExoQuick Ultra, but there is no significant difference in 
the mode size between qEV35 and qEV70. This may be 
due to the lack of capability of NTA to measure the 
smaller size of particles <70–90 nm as reported in pre-
vious studies.21 Other more sensitive particle size analysis 
methods such as nano-flow cytometry may be capable of 
revealing the difference.21 qEV35 provided a higher par-
ticle number compared with qEV70, which comes from 
a combination of more EVs and more contaminations, as 
confirmed from the flow cytometry analysis. To reveal the 
actual portions of EVs and lipoproteins, fluorescence- 
based NTA to specifically measure different targets can 
be used.44
Extensive comparison of EV separation has been made 
in the past few years.21,24,29,45 However, most of the 
studies are based on single-step separated samples, which 
indicates that the analytes may be interfered by soluble 
proteins or other non-EV impurities. One unique aspect for 
our immunomagnetic beads capture followed by flow 
cytometry analysis is that this capture plus detection cock-
tail allows specific analysis of EVs. By this sandwich 
assay, we can target EVs based on their specific markers 
or tumour-derived EVs based on cancer markers, so that 
false-positive signals from non-EV component can be 
eliminated to a great extent. We also used a mixture of 
EV markers for both the capture and detection to avoid 
possible EV heterogeneity among different people (eg one 
participant only has CD81 positive EVs but not CD9 
positive EVs or vice versa), yet EVs that only express 
CD63 may be missed.
In quantitative EV analysis such as EV-based clinical 
diagnosis, it is often critical to equally load the same EV 
amount for a reliable comparison of heterogenous samples 
to investigate the maker expression level. For example, 
previous studies have demonstrated that the fluorescence 
signal in flow cytometry was significantly affected by the 
number of EVs captured per beads.46 Protein amount and 
particle numbers are the two major loading dosages for 
quantitative EV analysis. Our results showed that the par-
ticle number measured by NTA has a linear relationship 
with EV amount measured by flow cytometry. This con-
firms our choice of using particle numbers as the dosage 
for EV loading. We also found that a linear relationship 
between protein amount and particle number only exists 
with qEV70 but not the other two separation kits. A failure 
of this linearity was also found from a previous study by 
Takov et al from certain SEC fractions.24 Therefore, it is 
important to investigate the correlation between the dosage 
and the analysis signal before making the decision about 
which dosage to use.
Our results and previous reports show that the EV quality 
and related analysis results largely depend on the separation 
method.29,37 However, no matter which method to use, the 
more significant aspect is whether the separated EVs can be 
used to generate clinically meaningful information. 
Although numerous studies compared different EV separa-
tion methods, surprisingly only a few of them employed 
plasma samples from cancer patients in the scenario of 
clinical cancer diagnosis.21,28–30,37 Therefore, we evaluated 
several EV metrics towards developing more accurate EV- 
based markers for improving PCa diagnosis and compared 
three separation kits. Unfortunately, these metrics could not 
differentiate PCa patients from HC. However, a larger num-
ber of samples are required before making any conclusive 
statement. Our ongoing work is to profile new cancer- 
specific biomarkers targeting cancer-derived EVs for 
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a better differentiation between PCa patients and HC in 
a multiplexed way. Immunomagnetic beads-based capture 
followed by flow cytometry analysis is ideal for this pur-
pose, as different fluorescence-encoded beads can be used 
from one sample and the results can be obtained from one 
analysis.47
In conclusion, we established a systematic assessment of 
the EV quality by comparing three latest commercially avail-
able separation kits. Our results show that EVs separated by 
the two SEC kits had a higher EV purity and lower protein 
contamination than those by ExoQuick Ultra. Between the 
two SEC kits, qEV35 demonstrated a higher EV yield, but 
with lower EV purity with a higher lipoprotein and protein 
contamination than qEV70. We particularly investigated the 
capability of using particle number to estimate the EV 
amount, which is important for quantitative clinical analysis. 
At last, we show that several common EV metrics including 
total EV level and PSA-specific EVs could not differentiate 
PCa patients from HC. Better EV associated cancer biomar-
kers are being investigated for this diagnosis purpose with 
a larger cohort in our following study.
We hope this work will raise awareness about the 
quality of EV preparations before conclusive statements 
are made on their biological functions or clinical mean-
ings. We provided here a complete workflow for the 
benchmarking of separation methods, which can be easily 
adopted by other researchers in the community. The com-
bination of EV separation using the commercial kit with 
magnetic-beads capture and flow cytometry analysis can 
be directly used as a general process used in clinical 
laboratories for EV-based cancer diagnosis.
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